A Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin in First Line Non-Squamous Non-Small Cell Lung Cancer (Nsq-Nsclc)

Cheol-Kyu Park,In-Jae Oh,Kyu-Sik Kim,Yoo-Duk Choi,Tae-Won Jang,Youn-Seup Kim,Kwan-Ho Lee,Kyeong-Cheol Shin,Chi Young Jung,Sei-Hoon Yang,Jeong-Seon Ryu,Seung-Hun Jang,Seung-Soo Yoo,Suk-Joong Yong,Kye Young Lee,Kwang-Ho In,Min-Ki Lee,Young-Chul Kim

CLINICAL LUNG CANCER（2017）

Cited 3|Views18

No score

Abstract

Aim: For patients with NSq-NSCLC, pemetrexed(A) plus cisplatin(P) was superior to gemcitabine(G) plus cisplatin(P) in terms of efficacy and toxicity. However, there have been no prospective phase III trial directly comparing the efficacy of AP with docetaxel + cisplatin (DP) in NSq-NSCLC. The objective of this study is to prove the non-inferiority of progression free survival (PFS) of DP compared to AP.

Translated text

Key words

Chemotherapy,Drug toxicity,East Asia,Progression-free survival,Treatment efficacy

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined